Blue Hole New Consumer Report, September 3 news, according to foreign news reports, Renault American Corporation (RAI) has submitted a set of pre-sale tobacco product applications (PMTA) to the US Food and Drug Administration (FDA) to seek authorization to proceed. Velo’s nicotine bag marketing order will enable these products to remain on the market after FDA review.

Velo is the group's modern oral product brand, which aims to provide adult tobacco consumers with innovative alternatives to traditional combustible and smokeless tobacco products.

Velo is a small white pouch made of nicotine derived from tobacco, but does not contain tobacco leaves. Unlike traditional dips, there is no need to spit out, and there is no residual odor. The submitted application group included varying levels of nicotine intensity and two flavors of Velo sachet products.

Like previous PMTA applications, these commercial proprietary applications provide the FDA with product analysis, information about human health risks, and evaluations that indicate that these Velo bags are suitable for protecting public health, including those for tobacco product users and non-users. Assessment.

James Figlar, executive vice president and head of scientific and regulatory affairs at RAI, said in a statement that Velo provides us with a space for innovation, allowing us to determine the next needs of adult tobacco consumers. Therefore, submitting the last batch of Velo branded PMTA is the next step in ensuring that adult tobacco consumers have acceptable products that can provide them with lifestyle choices. As the FDA begins to evaluate our industry’s collective PMTA after the September 9 deadline, it is vital that our chief regulatory agency continues to enforce enforcement of illegally sold tobacco products introduced after August 8, 2016.

The PMTA for the Velo bag is part of Reynolds' application to the FDA for seeking Velo nicotine agents and Vuse Vibe, Ciro and Solo electronic nicotine delivery systems.

The PMTA process allows FDA to assess whether these products should remain on the market as part of the FDA’s public health mission. Although this application contains relative risk information, the marketing order sought does not claim the revised risk.